Skip to main content
Premium Trial:

Request an Annual Quote

DVS Sciences Raises $14.6M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DVS Sciences today announced it has raised $14.6 million in a Series A financing round, which will be used to build up the company's manufacturing capabilities for its multiplexed single cell analysis technology.

The platform called CyTOF-Maxpar comprises a high-throughput mass cytometer for individual cell analysis and the company's Maxpar reagents. The technology can simultaneous identify up to 100 biomarkers with "very high" resolution and a wide dynamic range, DVS said, and the platform eliminates spectral overlap issues and enables quantitative, highly multiplexed biomarker analysis.

Spun out of the University of Toronto last year, DVS has offices in Toronto and Sunnyvale, Calif.

Investors in the Series A round include 5AM Ventures, Pfizer Venture Investments, Mohr Davidow, the Roche Venture Fund, and the Ontario Institute for Cancer Research.

"This significant Series A financing puts us in a position to broadly commercialize our innovative instrumentation and reagents to help scientists accelerate biomedical research, enable personalized therapeutic diagnosis and prognosis, and transform drug discovery," Scott Tanner, CEO and Co-founder of DVS, said in a statement.

Andrew Schwab, venture partner at 5AM Ventures, added, "We believe that the CyTOF-Maxpar platform will transform the performance of cellular analysis. By enabling massively multiplexed experiments, researchers will be primed to better understand the cellular dynamics of disease states, stem cells, and other biologically relevant systems."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.